
A Herpetologist Explores ‘Snake Island' — Home To The World's Largest Concentration Of Venomous Snakes
Despite their fearsome reputation, snakes and their lives are always a hot topic for humans. From keeping them as pets to watching them in action every chance we get, we've always found a way to keep snakes close.
In Manitoba, families crowd wooden platforms to watch tens of thousands of red-sided garter snakes mate en masse at the Narcisse Snake Dens. In Colorado, a rattlesnake 'mega den' livestreams newborns slithering between their mothers' coils, gaining fans and nicknames in the chatroom like 'Woodstock' and 'Agent 008.'
But not every serpent spectacle comes with a picnic table and a selfie spot. There is one island in Brazil where snakes reign supreme. A place so densely packed with venomous vipers that even the Brazilian government has barred civilians from setting foot on its shores.
Ilha da Queimada Grande, commonly known as Snake Island, lies off the coast of São Paulo and harbors an estimated 2,000 to 4,000 critically endangered golden lancehead pit vipers — though 2.0.CO;2.short">some studies suggest numbers are closer to the lower end. These snakes possess venom potent enough to rapidly immobilize prey and cause severe tissue destruction in humans.
Only a handful of researchers are granted access each year — and even they tread lightly.
Ilha da Queimada Grande wasn't always an island. Around 11,000 years ago, it was just a ridge along Brazil's southeastern coastline — until rising seas carved it off from the mainland, leaving whatever lived there to fend for itself.
And for one species of pit viper, life would never be the same again.
That snake was the Bothrops jararaca, a notorious mainland species responsible for many of Brazil's venomous snakebites. On the continent, it preyed on rodents and reptiles, but once isolated, its options changed rapidly.
Stranded without mammals and under constant pressure to catch fast-moving birds, a population of Bothrops jararaca slowly became something else entirely. Today, its descendant — the golden lancehead pit viper (Bothrops insularis) — is longer and deadlier. Found nowhere else but this forested rock, it has evolved venom so potent it can take down its prey with terrifying speed, ensuring that even a glancing bite can bag a meal before escape is possible.
This isolation rewrote the rules of survival for Bothrops insularis. On this island with no large predators, venom became this viper's greatest competitive advantage.
While 41 bird species have been recorded on Snake Island, the golden lancehead relies almost entirely on just two — the Chilean elaenia (Elaenia chilensis) and the yellow-legged thrush (Turdus flavipes). Both are migratory songbirds that arrive in seasonal waves. Elaenias arrive in late summer, and thrushes arrive in the winter.
Perhaps more importantly, both are just the right size and slow enough to catch.
Interestingly, the study noted that the southern house wren (Troglodytes musculus) — despite being the island's most abundant resident species — was able to avoid the viper's deadly fangs. And while the golden lancehead has been observed preying on other creatures like centipedes and lizards, it appears to make up an insignificant part of its diet.
The golden lancehead's preference for perching migratory birds has been forged by necessity. With no mammals and few reptiles to hunt, adult lanceheads have evolved to target these transient flocks with surgical precision. Their venom, the fastest-acting of any lancehead snake, ensures birds drop quickly — often before they have time to take flight.
Snakes even adjust their behavior to match their prey. While usually found coiled on the forest floor, lanceheads have been observed climbing trees during elaenia season, waiting motionless on branches to ambush birds mid-forage.
The golden lancehead's venom evolved for one job — to kill quickly. In fact, as mentioned in the video, the venom is almost 5 times more toxic than its mainland relatives, capable of killing human tissue, hemorrhaging the brain and triggering massive intestinal bleeding.
That biochemical brutality has made the snake a target for scientists and smugglers alike. On the black market, a single golden lancehead can fetch anywhere between $10,000 to $30,000.
And there's real promise of scientific breakthroughs. The venom of other Bothrops species have already shown pharmacological potential in the development of antitumoral compounds that could help in the treatment of certain cancers, according to a February 2024 study published in Toxicon. Another striking example of Bothrops venom's medical value is captopril — a groundbreaking blood pressure medication developed from Bothrops jararaca venom, which revolutionized the treatment of hypertension and paved the way for modern ACE inhibitors.
In that razor-thin space between danger and discovery, Ilha da Queimada Grande may yet hold the key to something greater. On an island where no human lives and few dare to walk, a critically endangered snake could one day save lives — demonstrating that even in the most hostile environments, nature continues to shape science in unexpected ways
While the golden lancehead may not make for a great pet, a lot of non-venomous snakes do. How well do you connect with your pet snake? Take the science-backed Pet Personality Test to find out now.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Start your period before age 10 — or after 15? How it can impact your lifelong health, from obesity to heart issues
Your period could be crampin' your style — and your future health. Girls are reaching puberty faster than previous generations, a phenomenon perplexing researchers. The average age of the start of menstruation decreased slightly from around 12.5 years in the 1950s and 1960s to 11.9 years for those born between 2000 and 2005. Research indicates that approximately 2% of girls begin menstruating after 15 — even fewer experience it before the age of 9. That's good news, as a new study out of Brazil links early or late menstruation onset to health struggles later in life. 'We now have evidence from a large Brazilian population that confirms how both early and late puberty can have different long-term health impacts,' said study author Flávia Rezende Tinano of the University of Sao Paulo. 'Most women can remember when they had their first period, but they might not realize that it could signal future health risks.' Tinano's team analyzed data from over 7,600 women 35 to 74 years old. The women were divided into three categories based on the timing of their first period — 'early' (less than 10 years old), 'typical' (10 to 15) or 'late' (older than 15). The participants' health was assessed through interviews, physical measurements, lab tests and ultrasound imaging. The researchers determined that women who began menstruating before age 10 were more likely to develop obesity, high blood pressure, diabetes, heart problems and reproductive problems like preeclampsia over time. Women who got their first period after 15 were less likely to be obese but more likely to have irregular periods and certain heart conditions. 'Understanding these links can help women and their doctors be more proactive about preventing conditions like diabetes, high blood pressure and heart disease,' Tinano said. The study was presented this week at the Endocrine Society's annual meeting in San Francisco. Menstruation is the monthly shedding of uterine lining, signaling that the woman is not pregnant. Past research has suggested a link between late menarche and an increased risk of osteoporosis, fractures and Alzheimer's disease. Starting menstruation later means delayed exposure to estrogen, a key hormone that protects and builds bone density. On the other hand, starting menstruation earlier means higher lifetime exposure to estrogen, which stimulates breast tissue growth and development and may create a hormonal imbalance. Early menarche has been associated with elevated risks of heart problems, Type 2 diabetes, breast cancer, anxiety and depression. Researchers haven't pinpointed exactly why girls are going through puberty earlier than before. Some have pointed to increased rates of childhood obesity, greater exposure to endocrine-disrupting chemicals and higher stress levels. Solve the daily Crossword


New York Post
15-07-2025
- New York Post
Start your period before age 10 — or after 15? How it can impact your lifelong health, from obesity to heart issues
Your period could be crampin' your style — and your future health. Girls are reaching puberty faster than previous generations, a phenomenon perplexing researchers. The average age of the start of menstruation decreased slightly from around 12.5 years in the 1950s and 1960s to 11.9 years for those born between 2000 and 2005. Advertisement 4 Girls are reaching puberty faster than previous generations, a phenomenon perplexing researchers. goodluz – Research indicates that approximately 2% of girls begin menstruating after 15 — even fewer experience it before the age of 9. That's good news, as a new study out of Brazil links early or late menstruation onset to health struggles later in life. Advertisement 'We now have evidence from a large Brazilian population that confirms how both early and late puberty can have different long-term health impacts,' said study author Flávia Rezende Tinano of the University of Sao Paulo. 'Most women can remember when they had their first period, but they might not realize that it could signal future health risks.' 4 The timing of a woman's first period may determine the health struggles she will face. KMPZZZ – Tinano's team analyzed data from over 7,600 women 35 to 74 years old. Advertisement The women were divided into three categories based on the timing of their first period — 'early' (less than 10 years old), 'typical' (10 to 15) or 'late' (older than 15). The participants' health was assessed through interviews, physical measurements, lab tests and ultrasound imaging. The researchers determined that women who began menstruating before age 10 were more likely to develop obesity, high blood pressure, diabetes, heart problems and reproductive problems like preeclampsia over time. 4 The average age of the start of menstruation decreased slightly from around 12.5 years in the 1950s and 1960s to 11.9 years for those born between 2000 and 2005. KMPZZZ – Advertisement Women who got their first period after 15 were less likely to be obese but more likely to have irregular periods and certain heart conditions. 'Understanding these links can help women and their doctors be more proactive about preventing conditions like diabetes, high blood pressure and heart disease,' Tinano said. The study was presented this week at the Endocrine Society's annual meeting in San Francisco. Menstruation is the monthly shedding of uterine lining, signaling that the woman is not pregnant. Past research has suggested a link between late menarche and an increased risk of osteoporosis, fractures and Alzheimer's disease. Starting menstruation later means delayed exposure to estrogen, a key hormone that protects and builds bone density. 4 'Understanding these links can help women and their doctors be more proactive about preventing conditions like diabetes, high blood pressure and heart disease,' the author of the new study said. JackF – Advertisement On the other hand, starting menstruation earlier means higher lifetime exposure to estrogen, which stimulates breast tissue growth and development and may create a hormonal imbalance. Early menarche has been associated with elevated risks of heart problems, Type 2 diabetes, breast cancer, anxiety and depression. Researchers haven't pinpointed exactly why girls are going through puberty earlier than before. Some have pointed to increased rates of childhood obesity, greater exposure to endocrine-disrupting chemicals and higher stress levels.
Yahoo
11-07-2025
- Yahoo
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
New report adds to growing evidence of iNKT cell therapy's potential in solid tumors NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication of another landmark case in Nature's Oncogene describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer, following treatment with agenT-797, MiNK's allogeneic iNKT cell therapy. Complete remission after failure on platinum-based chemotherapy, autologous stem cell transplant, and multiple ICIs (anti–PD-1, anti–CTLA-4, and anti–TIGIT) The publication, titled 'Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor,' presents a patient case from MiNK's clinical trial (NCT05108623). The patient had progressed after multiple lines of therapy—including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors (anti–PD-1, anti–CTLA-4, and anti–TIGIT)—and received a single infusion of agenT-797 alongside nivolumab. The patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later. Donor iNKT cells were detectable up to six months post-infusion, and treatment was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD). 'This case exemplifies the powerful potential of iNKT cells in treating even the most challenging cancers,' said Dr. Benjamin Garmezy, Assistant Director of Genitourinary Research for Sarah Cannon Research Institute at SCRI Oncology Partners. 'We observed a remarkable response in a patient who had exhausted standard and experimental treatments, offering compelling evidence to further pursue clinical studies of iNKT cell therapies in solid tumors.' Durable Responses & Immune Activation in Solid Tumors with Allo-iNKT Therapy These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors. At the 2025 inaugural AACR Immuno-Oncology meeting, MiNK presented data from its Phase 2 trial in 2L gastric cancer, demonstrating immune activation, increased tumor infiltration, and early signals of tumor control in patients previously refractory to checkpoint inhibitors. Notably, extended survival beyond 12 months was observed in several patients—an outcome rarely seen in this setting. These clinical observations were further reinforced in a separate peer-reviewed case report published in Oncogene, which described a patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free survival following a single infusion of agenT-797 in combination with nivolumab. Together, these data highlight the potential of agenT-797 to reshape the tumor microenvironment and deliver durable clinical activity, even in heavily pretreated, immunotherapy-resistant cancers. The ongoing Phase 2 trial in gastric cancer (NCT06251973) is actively enrolling, with additional readouts expected in upcoming months. You can access the full publication here. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company advancing a new class of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK's proprietary platform is designed to restore immune balance and drive cytotoxic responses across cancer, immune-mediated diseases, and pulmonary immune failure. The company's lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical development for graft-versus-host disease (GvHD), solid tumors, and severe pulmonary inflammation. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable highly specific immune targeting across tumor and tissue types. With a scalable manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to delivering accessible, durable, and broadly applicable immune reconstitution therapies. For more information, visit or follow us on X @MiNK_iNKT. Information important to investors is routinely posted to our website and social media channels. About AgenT-797 AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as 'master regulators,' combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors. Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al., AACR IO 2024; Oncogene, 2024), as well as reduce inflammation in critically ill patients with severe respiratory pathology (Nature Communications, 2024). Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Agenus with no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. CONTACT: Investor Contact 917-362-1370 investor@ Media Contact 781-674-4428 communications@